Skip to content
Therapy But Better – Lifestyle
Author:
Xyra, LLC
XYRA Announces First Patient Dosed in Europe in the Phase 2/3 HARBOR-AF Study of Budiodarone in Paroxysmal and Persistent Atrial Fibrillation
August 31, 2026